KMD held above its deeply discounted offer price in its trading return.
The verification of the company's dried flower product has been delayed.
Company considering implications of proposed change to regulate lab-developed tests like Cxbladder.
NZX-listed software company says UK partner can’t pay up; ASB to review lending.
The retailer delivered revenue growth but warned about slowing sales.
Shareholder happy with lower debt level, but board can’t commit to keeping it there.
The Warehouse will no longer be supplied Weet-Bix from later this week.
Mass spectrometer company’s new pharmaceutical-focused product has been released this month.
The $50m capital raising was underwritten by Goldman Sachs and Cannacord Genuity.
NZRegCo says three situations have occurred in last five years where it would have contemplated its new alert tool.
